Loading
Life sciences · Journal article
World Journal of Clinical Oncology · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Lung cancer, responsible for the highest number of cancer-related deaths globally, comprises small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), two subtypes with fundamentally different molecular mechanisms and disease trajectories. The tumor-suppressive microRNA miR-204 is frequently inactivated in lung cancer and plays a central role in driving progression and metastasis. Recent work has uncovered striking differences in how miR-204 is downregulated in each subtype. In SCLC, the RNA-binding protein HuD stabilizes oncogenic long non-coding RNAs (lncRNAs) and PFN2 mRNA, leading to reduced miR-204-5p levels and increased cell migration. By contrast, in NSCLC, epigenetic silencing via miR-204 promoter hypermethylation decreases its expression, derepressing NUAK1, activating mTOR signaling, and promoting tumor progression. Despite operating through distinct pathways, both mechanisms converge on miR-204 loss to foster malignancy. This minireview summarizes these recent insights into the HuD-lncRNA axis and epigenetic regulation of miR-204, evaluates their clinical implications, and discusses emerging multimodal approaches that target the miR-204 network for more effective precision therapy in lung cancer.